Fitness & Wellness Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Fitness & Wellness Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Recent findings from University of Tokyo highlight research in breast cancer
July 2nd, 2008
According to recent research published in the journal Breast Cancer Research and Treatment, " Several randomized controlled trials have confirmed the usefulness of trastuzumab as an adjuvant therapy for HER2-overexpressed breast cancer patients; however, the costs for 1-year treatment are high. Therefore, we performed an economic analysis regarding the efficient distribution of medical resources." " To analyze the cost-effectiveness for a 1-year adjuvant trastuzumab treatment group compared with the observation group, we constructed a Markov model adopting a 3% per year discount rate for costs and outcomes. The time horizon was 50 years. The perspective was that...
Source: Fitness & Wellness Business Week (2008-07-02)
|
